Radiopharm Theranostics Financials - Benzinga

Radiopharm Theranostics Ltd

RADXNASDAQ

Trade with Public

Trade with Public

$2.44

N/A

At close: Aug 24, 5:00 PM EST

$2.39

-0.05-2.05%

After Hours: 4:32 PM EST

Overview News Events Price TargetsFinancialsSentiment Compare Stock Report

Radiopharm Theranostics Financials

Radiopharm Theranostics (RADX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Radiopharm Theranostics Says Cash And Cash Equivalents Of Approximately $34.52m For Or The 6 Months Ended December 31, 2025 Provide Runway Into 2027

Program and Business Updates18F-RAD101 – Small molecule targeting fatty acid synthase radiolabeled with Fluorine-18RAD 101 is being evaluated in a single-arm U.S. Phase 2b clinical trial for the diagnostic performance of

Benzinga Newsdesk

PRO
Radiopharm Theranostics Reported FY25 Cash Balance Of $29.12M, Operating Cash Flow Of $36.67M, Confirmed Guidance of Cash Runway Through To Mid-2026

Financial updateThe following is a summary of the Appendix 4C Cash Flow Report:The year-end closing cash balance was $29.12 million, a rise from $18.58 million at the close of the previous year.Net cash outflows from

Benzinga Newsdesk